Activity of the CD40 antagonistic antibody lucatumumab – insights from CLL-niche mimicking xenografts and fludarabine combinations

Marius StiefelhagenDepartment of Medicine I, Laboratory of Lymphocyte Signaling and Oncoproteome, Excellence Cluster for Cellular Stress Response and Aging-Associated Diseases (CECAD), University of Cologne, Germany;

Carola GigelDepartment of Medicine I, Laboratory of Lymphocyte Signaling and Oncoproteome, Excellence Cluster for Cellular Stress Response and Aging-Associated Diseases (CECAD), University of Cologne, Germany;

Elena VasyutinaDepartment of Medicine I, Laboratory of Lymphocyte Signaling and Oncoproteome, Excellence Cluster for Cellular Stress Response and Aging-Associated Diseases (CECAD), University of Cologne, Germany;

Michael MöllmannClinic of Hematology, University Hospital of Essen, Germany

Alexandra BreuerDepartment of Medicine I, Laboratory of Lymphocyte Signaling and Oncoproteome, Excellence Cluster for Cellular Stress Response and Aging-Associated Diseases (CECAD), University of Cologne, Germany;

Petra MayerDepartment of Medicine I, Laboratory of Lymphocyte Signaling and Oncoproteome, Excellence Cluster for Cellular Stress Response and Aging-Associated Diseases (CECAD), University of Cologne, Germany;

Jan DürigClinic of Hematology, University Hospital of Essen, Germany

Marco HerlingDepartment of Medicine I, Laboratory of Lymphocyte Signaling and Oncoproteome, Excellence Cluster for Cellular Stress Response and Aging-Associated Diseases (CECAD), University of Cologne, Germany; Correspondence[email protected]

show all

Click to increase image sizeClick to decrease image size

Acknowledgements

Novartis provided HCD122, however, had no role in study design, data collection, and data analysis as well as in the decision to publish or in the preparation of the manuscript.

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article at http://dx.doi.org/10.3109/10428194.2015.1135433.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Activity of the CD40 antagonistic antibody lucatumumab – insights from CLL-niche mimicking xenografts and fludarabine combinations

Potential conflict of interest

Information for

Open access

Opportunities

Help and information

Activity of the CD40 antagonistic antibody lucatumumab – insights from CLL-niche mimicking xenografts and fludarabine combinations

Acknowledgements

Potential conflict of interest

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature